Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance

Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide, bicalutamide, and newly approved enzalutamide mainly target the hormone binding pocket (HBP) of AR. However, over time, drug resistance i...

Full description

Bibliographic Details
Main Authors: Xiaohong eTian, Yang eHe, Jinming eZhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-03-01
Series:Frontiers in Pharmacology
Subjects:
Drug Resistance
Mutation
androgen receptor
antiandrogen
Rational drug design.
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00057/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fphar.2015.00057/full

Similar Items